Dyax Announces Appointment of Dr. Burt Adelman as Chief Medical Officer
Dyax Corp. announced the appointment of Burt Adelman, M.D. as Chief Medical Officer. Dr. Adelman will lead the development and regulatory strategy for the Company's non-histamine-mediated angioedema franchise.
Dr. Adelman has experience and expertise in drug development and commercialization. He led the successful development of a number of important biologic and small molecule therapeutics, including Angiomax®, Avonex®, Amevive® and Tysabri®. Dr. Adelman began his career with Biogen Idec (then Biogen) in 1991 as Director of Medical Research, and held positions of increasing responsibility including Vice President, Regulatory Affairs, Vice President, Development Operations, and Executive Vice President, Research and Development. He retired from Biogen Idec as Executive Vice President of Portfolio Strategy in 2007. Dr. Adelman serves as a lecturer in medicine at the Harvard Medical School, and was Associate Professor of Medicine at the Medical College of Virginia, and Chief of the Hematology-Oncology service at the Hunter Holmes McGuire VA Medical Center.
Other news from the department people
